Nitisinone
Product Specifications
Background
Inhibitor of 4-Hydroxyphenylpyruvate dioxygenase (HPPD; IC50 = 40 nM1 and 173 nM2) and is in clinical use for the treatment of hereditary tyrosinemia type 13. CD13+ cancer stem cells (CSCs) are dependent on aerobic metabolism of tyrosine - Nitisinone inhibition of tyrosine metabolism results in lowered availability of acetyl-CoA and fumarate for use in the citric acid cycle causing these CSCs to enter cell cycle, decreasing self-renewal, and making them more susceptible to chemotherapy.4 Nitisinone is a potential treatment option for cancers that rely on tyrosine metabolism.
Conjugation
Unconjugated
Buffer
Beige solid
Storage Conditions
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ARP37018_P050-FITC 100 µL
Atf4 Antibody : FITC (ARP37018_P050-FITC)
Sign In for Pricing
View Details 172065-AF-ML490 100 µL
CD79a (B lymphocyte-specific MB1 Protein, B Cell antigen receptor complex-Associated Protein alpha chain, CD79a Molecule immunoglobulin Associated alpha, Ig-alpha, IGA, IgM-alpha, Immunoglobulin-Associated alpha, Ly54, MB-1 Membrane GlycoProtein, Membrane-bound immunoglobulin-Associated Protein, Surface IgM-Associated Protein) (BSA & Azide Free) (MaxLight 490)
Sign In for Pricing
View Details 
GTR15345457 1 Vial
Lentiviral human PPM1K shRNA (UAS) - Lentiviral human PPM1K shRNA (UAS, GFP) plasmid
Sign In for Pricing
View Details MBS7053423-01 0.5 mg (E-Coli)
Recombinant Human Thyrotropin subunit beta R55G Mutant (TSHBmut)
Sign In for Pricing
View Details MBS7053423-02 0.05 mg (Baculovirus)
Recombinant Human Thyrotropin subunit beta R55G Mutant (TSHBmut)
Sign In for Pricing
View Details